GlobeNewswire: Spero Therapeutics, Inc. Contains the last 10 of 190 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:44:35ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/13/2845822/0/en/Spero-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Operating-Results-and-Provides-a-Business-Update.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update2024-03-13T20:01:00Z<![CDATA[CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.]]>https://www.globenewswire.com/news-release/2024/03/06/2841401/0/en/Spero-Therapeutics-to-Provide-Business-Update-and-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-Wednesday-March-13-2024.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 20242024-03-06T13:05:00Z<![CDATA[CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.]]>https://www.globenewswire.com/news-release/2024/02/28/2836936/0/en/Spero-Therapeutics-Announces-Clearance-of-IND-for-SPR206-to-Treat-MDR-Gram-negative-Bacterial-Infections.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections2024-02-28T13:05:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study. SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.]]>https://www.globenewswire.com/news-release/2024/02/26/2835109/0/en/Spero-Therapeutics-to-Present-at-Cowen-s-44th-Annual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference2024-02-26T13:05:00Z<![CDATA[CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place March 4-6, 2024, at the Boston Marriott Copley Place in Boston, MA. Details are as follows:]]>https://www.globenewswire.com/news-release/2024/01/31/2821549/0/en/Spero-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2024-01-31T21:05:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on January 29, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 50,000 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs are being granted as inducements material to the new employee becoming an employee of Spero in accordance with Nasdaq Listing Rule5635(c)(4).]]>https://www.globenewswire.com/news-release/2024/01/05/2804625/0/en/Spero-Therapeutics-Provides-Corporate-Update-and-2024-Outlook.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics Provides Corporate Update and 2024 Outlook2024-01-05T13:05:00Z<![CDATA[In 2H 2024, expect to provide Phase 2a topline proof-of-concept data from our wholly-owned lead program SPR720 in NTM-PD patients]]>https://www.globenewswire.com/news-release/2024/01/02/2802657/0/en/Spero-Therapeutics-Announces-First-Patient-First-Visit-for-Phase-3-PIVOT-PO-Trial-Evaluating-Tebipenem-HBr-in-Complicated-Urinary-Tract-Infections.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections2024-01-02T13:05:00Z<![CDATA[$95 million in development milestones payable over two years, as part of GSK license agreement $95 million in development milestones payable over two years, as part of GSK license agreement]]>https://www.globenewswire.com/news-release/2023/11/13/2779452/0/en/Spero-Therapeutics-Announces-Third-Quarter-2023-Operating-Results-and-Provides-a-Business-Update.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update2023-11-13T21:05:00Z<![CDATA[Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023]]>https://www.globenewswire.com/news-release/2023/11/06/2774092/0/en/Spero-Therapeutics-to-Provide-Business-Update-and-Report-Third-Quarter-2023-Financial-Results-on-Monday-November-13-2023.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 20232023-11-06T13:05:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.]]>https://www.globenewswire.com/news-release/2023/11/01/2771695/0/en/Spero-Therapeutics-to-Present-at-Upcoming-November-Investor-Conferences.html?f=22&fvtc=4&fvtv=37928Spero Therapeutics to Present at Upcoming November Investor Conferences2023-11-01T20:05:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer, will be available for one-on-one meetings at the Truist Securities BioPharma Symposium, to be held at the Lotte New York Palace in New York, NY, on November 8-9, 2023 and will present and be available for one-on-one meetings at the 6th Annual Evercore ISI HealthCONx Conference to be held at the Kimpton EPIC Miami Hotel in Miami, FL, on November 28-30, 2023. Details are as follows:]]>